Dipender Gill Raises Questions About Cardiovascular Risk and IL-6 Inhibition in ZEUS

Coverage, in order

1. 2d ago
   
   OncoDaily obscure study

   Dipender Gill Raises Questions About Cardiovascular Risk and IL-6 Inhibition in ZEUS

   Dipender Gill, Chief Executive Officer of Sequoia Genetics, shared on LinkedIn: “Did ZEUS select patients at high cardiovascular risk, but with relatively little risk that was modifiable through IL-6 inhibition?

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.